First Light Asset Management, LLC
13F filer · CIK 0001600004Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$1.65BU.S. long equity reported on 13F
Positions312 new · 6 closed
Net flow last quarter+$136MBuys minus sells
Top 10 positions weight60.7%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202631 positions | |||||
| $179M | 10.89% | 9.60% | +26.2% | Q4 2013 | |
| $133M | 8.06% | 18.18% | +51.8% | Q2 2019 | |
| $127M | 7.72% | 5.12% | -31.3% | Q3 2020 | |
| ATAPGEApogee Therapeutics, Inc. | $123M | 7.50% | 1.23% | +61.3% | Q4 2025 |
| $118M | 7.17% | 5.36% | -21.3% | Q3 2025 | |
| $74.9M | 4.55% | 1.16% | -17.2% | Q4 2024 | |
| $69.1M | 4.20% | 1.86% | +574.1% | Q1 2026 | |
| $66.3M | 4.03% | 0.33% | +57.5% | Q4 2022 | |
| $54.7M | 3.32% | 16.51% | +3.5% | Q4 2020 | |
| $54.3M | 3.30% | 2.71% | -5.3% | Q3 2025 | |
| $53.8M | 3.27% | 2.63% | +222.7% | Q1 2026 | |
| $51.1M | 3.11% | 13.81% | +6.1% | Q3 2018 | |
| $51.1M | 3.10% | 4.87% | +157.4% | Q1 2018 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $50.9M | 3.10% | 1.29% | +24.9% | Q4 2021 |
| $45.5M | 2.76% | 8.35% | +16.3% | Q1 2025 | |
| $44.5M | 2.70% | 1.02% | +9.3% | Q4 2024 | |
| $39.3M | 2.39% | 2.00% | -31.4% | Q2 2023 | |
| $39.1M | 2.38% | 1.47% | New | Q2 2026 | |
| $32.3M | 1.96% | 2.11% | +31.4% | Q4 2025 | |
| $29.8M | 1.81% | 10.66% | +29.3% | Q1 2026 | |
| $27.5M | 1.67% | 4.16% | +23.6% | Q3 2025 | |
| $25.5M | 1.55% | 17.17% | -0.5% | Q3 2019 | |
| $22.2M | 1.35% | Not reported | -0.7% | Q4 2024 | |
| $21.2M | 1.29% | 0.83% | -19.9% | Q1 2025 | |
| $20.1M | 1.22% | 0.24% | +143.4% | Q1 2024 | |
| $19.9M | 1.21% | 0.51% | -0.6% | Q3 2023 | |
| $18.8M | 1.14% | 0.99% | -7.7% | Q4 2013 | |
| $15.9M | 0.97% | 1.12% | -22.2% | Q4 2013 | |
| $14.2M | 0.86% | 7.34% | -10.1% | Q4 2018 | |
| $13.8M | 0.84% | 2.04% | Not reported | Q1 2023 | |
| $9.52M | 0.58% | 0.12% | -1.6% | Q3 2025 | |
| Q1 2026Reported May 15, 202635 positions | |||||
| $133M | 11.88% | 7.53% | -23.5% | Q3 2020 | |
| $122M | 10.96% | 6.85% | +38.3% | Q3 2025 | |
| $72.2M | 6.47% | 7.50% | -3.0% | Q4 2013 | |
| $67.6M | 6.06% | 12.11% | +6.4% | Q2 2019 | |
| CPCNTACentessa Pharmaceuticals PLC | $62M | 5.56% | 1.01% | -31.5% | Q1 2024 |
| ATAPGEApogee Therapeutics, Inc. | $48.5M | 4.35% | 0.77% | +102.4% | Q4 2025 |
| $44.3M | 3.97% | 2.87% | -4.9% | Q3 2025 | |
| $41.8M | 3.74% | 1.41% | -23.0% | Q4 2024 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $39.6M | 3.55% | 1.03% | -8.8% | Q4 2021 |
| $37.2M | 3.33% | 16.23% | +25.6% | Q4 2020 | |
| $32.3M | 2.90% | 7.25% | +82.3% | Q1 2025 | |
| $31.6M | 2.83% | 0.93% | -36.3% | Q4 2024 | |
| $31.4M | 2.81% | 1.95% | -12.5% | Q2 2023 | |
| $31.1M | 2.79% | 13.03% | +33.7% | Q3 2018 | |
| $25.9M | 2.32% | 0.21% | -4.9% | Q4 2022 | |
| $25.2M | 2.26% | 1.92% | +20.7% | Q1 2018 | |
| $20.8M | 1.87% | 1.44% | -37.9% | Q4 2013 | |
| $20.3M | 1.82% | 8.25% | New | Q1 2026 | |
| $20M | 1.79% | 3.44% | Not reported | Q3 2025 | |
| $19.8M | 1.78% | 0.51% | +9.3% | Q3 2023 | |
| $17.6M | 1.58% | 1.63% | +18.1% | Q4 2025 | |
| $17.5M | 1.57% | 1.05% | -17.5% | Q1 2025 | |
| $16.4M | 1.47% | 17.46% | -0.3% | Q3 2019 | |
| $16.4M | 1.47% | 1.08% | Not reported | Q4 2013 | |
| $16.3M | 1.46% | 8.17% | -10.5% | Q4 2018 | |
| $15.6M | 1.40% | 0.82% | New | Q1 2026 | |
| $13.4M | 1.20% | 0.96% | -0.5% | Q4 2025 | |
| $12.6M | 1.13% | 0.49% | -63.9% | Q1 2024 | |
| $11.2M | 1.01% | 1.91% | -6.5% | Q4 2024 | |
| $10.7M | 0.96% | Not reported | -5.4% | Q4 2024 | |
| $9.72M | 0.87% | 1.12% | New | Q1 2026 | |
| $8.29M | 0.74% | 2.72% | -9.4% | Q2 2025 | |
| $8.24M | 0.74% | 0.10% | Not reported | Q1 2024 | |
| $7.91M | 0.71% | 0.33% | New | Q1 2026 | |
| $7.58M | 0.68% | 0.13% | -70.5% | Q3 2025 | |
| Q4 2025Reported Feb 17, 202632 positions | |||||
| $171M | 13.10% | 11.09% | -9.9% | Q3 2020 | |
| $118M | 9.02% | 7.78% | +1.1% | Q4 2013 | |
| $99.2M | 7.59% | 11.53% | +162.4% | Q2 2019 | |
| $74.2M | 5.67% | 5.73% | +31.0% | Q3 2025 | |
| CPCNTACentessa Pharmaceuticals PLC | $57M | 4.36% | 1.53% | -37.3% | Q1 2024 |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $55.6M | 4.25% | 1.25% | +26.8% | Q4 2021 |
| $46.5M | 3.56% | 2.36% | +32.0% | Q4 2013 | |
| $44M | 3.37% | 1.36% | +71.5% | Q1 2024 | |
| $41.5M | 3.18% | 1.38% | +126.3% | Q3 2025 | |
| $40.5M | 3.10% | 3.05% | 0.0% | Q3 2025 | |
| $39.1M | 2.99% | 1.48% | +11.2% | Q4 2024 | |
| $38.9M | 2.98% | 0.29% | +479.2% | Q3 2025 | |
| $36.2M | 2.77% | 1.86% | -4.5% | Q4 2024 | |
| $35.9M | 2.74% | 9.77% | +156.5% | Q3 2018 | |
| $31.7M | 2.42% | 0.44% | +63.9% | Q3 2025 | |
| $31.5M | 2.41% | 0.99% | New | Q4 2025 | |
| $31.3M | 2.40% | 2.31% | -34.7% | Q2 2023 | |
| $30.9M | 2.36% | 17.93% | -3.9% | Q3 2019 | |
| $30.1M | 2.30% | 0.23% | +5.3% | Q4 2022 | |
| $27.3M | 2.09% | 0.48% | -0.8% | Q3 2023 | |
| $27.2M | 2.08% | 1.27% | -10.8% | Q1 2025 | |
| $25.4M | 1.94% | 13.31% | +92.6% | Q4 2020 | |
| $24.5M | 1.87% | 9.08% | -7.0% | Q4 2018 | |
| $23.9M | 1.83% | 1.60% | Not reported | Q1 2018 | |
| ATAPGEApogee Therapeutics, Inc. | $21.5M | 1.64% | 0.42% | New | Q4 2025 |
| $20.8M | 1.59% | 4.02% | -0.8% | Q1 2025 | |
| $20.6M | 1.57% | 2.05% | -16.8% | Q4 2024 | |
| $20M | 1.53% | 3.04% | -48.5% | Q2 2025 | |
| $17.3M | 1.32% | 1.39% | New | Q4 2025 | |
| $12M | 0.91% | 0.11% | -7.6% | Q3 2025 | |
| $10.7M | 0.82% | Not reported | +149.3% | Q4 2024 | |
| $3.04M | 0.23% | 0.09% | Not reported | Q3 2020 | |
| Q3 2025Reported Nov 14, 202541 positions | |||||
| $104M | 9.76% | 12.59% | +28.2% | Q3 2020 | |
| PHPHLTPerformant Healthcare, Inc. | $90.6M | 8.54% | Not reported | -11.0% | Q3 2021 |
| CPCNTACentessa Pharmaceuticals PLC | $88.2M | 8.31% | 2.70% | -15.3% | Q1 2024 |
| $76.6M | 7.22% | 7.70% | +45.0% | Q4 2013 | |
| $45.6M | 4.30% | 3.06% | New | Q3 2025 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $39.2M | 3.70% | 1.00% | +9.0% | Q4 2021 |
| $38.3M | 3.61% | 19.03% | +9.9% | Q3 2019 | |
| $33.9M | 3.20% | 4.88% | New | Q3 2025 | |
| $33.6M | 3.17% | 1.97% | +26.4% | Q4 2024 | |
| $32.3M | 3.04% | 2.42% | New | Q3 2025 | |
| $31.6M | 2.98% | 5.91% | +10.6% | Q2 2025 | |
| $31.4M | 2.96% | 1.79% | -12.3% | Q4 2013 | |
| $30.3M | 2.86% | 3.59% | -72.0% | Q2 2023 | |
| $28.2M | 2.66% | 4.43% | +9.5% | Q2 2019 | |
| CTCDTXCidara Therapeutics, Inc. | $28M | 2.64% | 1.00% | +62.0% | Q2 2025 |
| $26.7M | 2.51% | 0.48% | -17.2% | Q3 2023 | |
| $25.5M | 2.40% | 2.47% | +89.5% | Q4 2024 | |
| $23M | 2.16% | 1.34% | -17.5% | Q4 2024 | |
| $22M | 2.07% | 6.95% | +135.2% | Q4 2020 | |
| MMRUSMerus N.V. | $21.1M | 1.99% | 0.30% | New | Q3 2025 |
| $18.2M | 1.72% | 0.27% | New | Q3 2025 | |
| $17.5M | 1.65% | 0.22% | +117.3% | Q4 2022 | |
| $17.3M | 1.63% | 9.78% | -3.3% | Q4 2018 | |
| $17.1M | 1.62% | 1.44% | +0.3% | Q1 2025 | |
| $15.7M | 1.48% | 0.45% | +12.3% | Q2 2025 | |
| $15.3M | 1.44% | 0.66% | New | Q3 2025 | |
| $14.7M | 1.39% | 0.79% | -9.9% | Q1 2024 | |
| $14M | 1.32% | 4.09% | -1.5% | Q1 2025 | |
| $11.9M | 1.12% | 0.14% | -8.8% | Q2 2025 | |
| $11.6M | 1.09% | 3.81% | +115.0% | Q3 2018 | |
| $8.59M | 0.81% | 0.30% | -47.9% | Q2 2019 | |
| $8.15M | 0.77% | 0.15% | New | Q3 2025 | |
| $7.85M | 0.74% | 44.12% | -49.6% | Q4 2024 | |
| $5.54M | 0.52% | 0.07% | -5.7% | Q3 2024 | |
| $5.53M | 0.52% | 0.11% | +61.5% | Q3 2023 | |
| $5.29M | 0.50% | 0.05% | New | Q3 2025 | |
| $4.61M | 0.43% | 0.46% | -26.2% | Q4 2023 | |
| $3.54M | 0.33% | 0.10% | -47.1% | Q1 2025 | |
| $3.22M | 0.30% | 0.05% | -38.5% | Q2 2025 | |
| $3.18M | 0.30% | 1.08% | New | Q3 2025 | |
| $2.18M | 0.21% | Not reported | -79.4% | Q4 2024 | |
Premium opens every quarter this fund has filed